Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer

Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer

Background and purpose: Inhibitors of poly (ADP-ribose) polymerase (PARPi) has been shown in multiple clinical trials to benefit survival in patients with homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). Fluzoparib has been approved for...

Full description

Bibliographic Details
Main Author: WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei
Format: Article
Language:English
Published: Editorial Office of China Oncology 2021-07-01
Series:Zhongguo aizheng zazhi
Subjects:
prostate cancer| fluzoparib| homologous recombination repair deficiency| efficacy
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/20210701.pdf

Internet

http://www.china-oncology.com/fileup/1007-3639/PDF/20210701.pdf

Similar Items